Dusseldorf - Delayed Quote EUR

Daiichi Sankyo Co Ltd (D4S.DU)

22.51

+0.33

+(1.49%)

At close: May 21 at 7:30:56 PM GMT+2

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

Zacks yesterday

4568.T

PFE
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial

The global trial was initiated based on outcomes from the earlier IDeate-PanTumor01 Phase I/II trial.

Clinical Trials Arena yesterday

4568.T
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

BASKING RIDGE, N.J. & RAHWAY, N.J., May 19, 2025--The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with disease progression following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.

Business Wire 2 days ago

MRK

DSKYF

DSNKY
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

The Wall Street Journal 9 days ago

069620.KS

CHGCF

CHGCY
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

Clinical Trials Arena 13 days ago

AZN

4568.T
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J., May 07, 2025--ENHERTU Followed by THP Showed Statistically Significant Improvement in pCR in HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Trial

Business Wire 14 days ago

DSKYF

DSNKY
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 19 days ago

TAK

4568.T
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

Clinical Trials Arena 29 days ago

4568.T

AZN
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab) as a first-line treatment in patients with HER2-positive metastatic breast cancer. High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningf

Benzinga 30 days ago

AZN

4568.T
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

TOKYO & BASKING RIDGE, N.J., April 21, 2025--ENHERTU Combination Demonstrated Statistically Significant Improvement in PFS vs. THP as First-Line Therapy in HER2 Positive Metastatic Breast Cancer

Business Wire 30 days ago

DSKYF

DSNKY
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks last month

4568.T

TAK
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

The Wall Street Journal last month

TAK

TKPHF

DSKYF
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH, April 08, 2025--DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.

Business Wire last month

DSKYF

DSNKY
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

The approval is supported by the outcomes of the Phase III DESTINYBreast06 trial.

Pharmaceutical Technology last month

4568.T

AZN
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TOKYO & MUNICH, April 04, 2025--ENHERTU® Approved in the EU as 1st HER2 Directed Therapy for Patients with HR+, HER2 Low or HER2 Ultralow mBC Following at Least 1 Endocrine Therapy

Business Wire last month

DSKYF

DSNKY
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks last month

4568.T

TAK
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

TOKYO & BASKING RIDGE, N.J., March 31, 2025--DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

Business Wire last month

DSKYF

DSNKY
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial

The trial enrolled 494 subjects in Europe, South America, and Asia.

Clinical Trials Arena 2 months ago

4568.T

AZN
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J., March 03, 2025--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer

Business Wire 2 months ago

DSKYF

DSNKY
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TOKYO & MUNICH, February 28, 2025--ENHERTU® Recommended for Approval in the EU by CHMP for HER2 Low or Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Business Wire 2 months ago

DSKYF

DSNKY

Performance Overview

Return	D4S.DU	Nikkei 225 (^N225)
YTD	-361.45%	-7.30%
1-Year	-23,577.39%	-4.23%
3-Year	+559,699,350.00%	+38.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daiichi Sankyo Co Ltd (D4S.DU)

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Performance Overview